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Brain metastasis is common in patients with melanoma and represents a signiﬁcant cause of morbidity and mortality. There
have been no speciﬁc randomized trials for patients with melanoma brain metastasis, so treatment is based on management of
brain metastasis in general and requires multidisciplinary expertise including radiation oncology, neurosurgery, medical oncology,
and palliative care. In this paper, we summarize the prognosis, general management, and the role of radiation therapy in the
management of metastatic melanoma in the brain.
1.Introduction
Metastatic melanoma in the brain is a serious event in
patients with melanoma because of the poor prognosis and
potential impact on quality of life. Symptomatic metastases
represent the initial site of metastatic spread in 20% but
may occur at any time during the course of the disease
[1]. Autopsy data have shown that up to 75% of patients
who died from metastatic melanoma had brain metastases
[2, 3]. Two large institutional series of 686 and 702 patients
[3, 4] indicate a generally poor outcome, with the majority
(up to 95%) dying directly from brain metastases. The
median survival of patients with multiple metastases was
approximately 3-4 months. There were some diﬀerences in
survival according to treatment received, being 8.9 months
for surgery plus whole brain radiotherapy (WBRT), 8.7
months for surgery alone, 3.4 months for WBRT alone,
and 2.1 months for supportive care. These diﬀerences are a
probable reﬂection of patient selection based on the number
of cerebral metastasis, performance status, and extent of
extracranial metastasis.
2. Prognostic Factors for Survival
The Radiation Therapy Oncology Group Recursive Par-
titioning Analysis (RPA) Classes have been validated in
melanoma [5]. Age (>65 year old) and the number of neuro-
logical symptoms (weakness and fatigue) are associated with
poorer survival [6]. Ulceration and location on the head and
neck region are two main primary tumour characteristics
that are associated with poorer survival [6]. The number
of cerebral metastases is a signiﬁcant prognostic factor with
better prognosis seen in single or oligometastatic disease (2-
3 cerebral metastases). Patients with more than 3 metastases
had a median survival of 3.5 months compared with 5.9
months for those with 3 or less metastases (p = 0.005).
More recently, there is debate on whether it is the number
of metastases or the overall intracranial tumour volume
that is the relevant factor [7]. The worst outcome is seen
in patients with leptomeningeal disease [8]. In all large
cohorts of patients with melanoma brain metastases, the
absence of extracranial disease was a positive prognostic
factor.2 International Journal of Surgical Oncology
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Figure 1: Approaches for management of melanoma brain metastasis.
MD Anderson Cancer Center analysed the outcomes
of 743 patients with metastatic melanoma in the brain
treated between 1986 and 2004 [9]. On multivariate analysis,
the date of diagnosis was a prognostic factor. The median
survival for patients diagnosed before 1996 was 4.14 months
compared with 5.92 months for patients diagnosed in 1996
orlater(HR0.7595%CI0.59–0.95, p = 0.02).Theincreased
use of MRI as a screening tool for brain metastases over
time may have contributed to this improvement. In addition,
earlier diagnosis of patients with lower burden, asymp-
tomatic brain metastasis might allow for more frequent use
oflocallydirectedtreatmentsuchasstereotacticradiosurgery
or surgical excision. A similar study of patients from the
Memorial Sloan Kettering Cancer Center noted that age >65,
presence of extracranial metastases, presence of neurologic
symptoms and four or more metastases are predictors for
poorer survival, although some of these features are self-
predicting in that more aggressive treatment options are less
likely to be oﬀered [10].
3. GeneralManagement
The management of metastatic melanoma in the brain
depends on the combination of patient, tumor, and treat-
ment factors. The dominant factor determining manage-
ment has been the number of cerebral metastases. With
the wider availability of stereotactic radiosurgery facilities
enabling the eﬀective treatment of multiple metastases in
a single treatment session, the absolute number of cerebral
metastases is now less important than previously. Reports
increasingly suggest that the use of stereotactic radiosurgery
to treat multiple metastases may have merit, particularly if
there are less than 10 lesions, all under 3cm in size and
with limited oedema or mass eﬀect [11–13]. Recent data
suggested that the total volume of the metastatic lesions
rather than the number of metastases was the limiting factor
for radiosurgery technique [7].
Our general approach in the management of melanoma
metastasesinthebrainisshowninFigure 1.Forpatientswith
a single or oligometastases, the management depends on the
performance status, neurological status, the characteristic of
themetastases(number,size,andlocation),andtheextentof
the extracranial disease. Patients in the RPA class 3 are man-
aged with steroids in conjunction with WBRT. Those with
more favourable characteristics should be considered for
more aggressive local treatment of the individual metastasis.
The two options of local treatment are surgical excision and
stereotactic radiosurgery. Surgery has a role in conﬁrming
the diagnosis especially as there is no clear relationship
between the primary melanoma and the development of
brain metastasis. In addition, surgical resection can also
provide quick relief in symptoms associated with disease
such as shunting in hydrocephalus. The relative advantages
and disadvantages of each technique are summarised in
Table 1.
4.Multiple Metastases
Patients with multiple metastases are generally not suitable
foraggressivelocaltreatment.Theprognosisispoor,withthe
majority succumbing to progressive intracranial metastases
within months, irrespective of treatment. Application ofInternational Journal of Surgical Oncology 3
Table 1: Relative advantage of surgery and stereotactic radiosurgery for single or oligobrain metastases.
Surgery Stereotactic radiosurgery
Indications
(i) When histological conﬁrmation is needed.
(ii) Single or “dominant” lesion.
(iii) Prominent cystic component or necrosis.
(iv) Prior radiosurgery treatment failure.
(i) Lesion in eloquent locations.
(ii) Oligometastatic disease.
(iii) When lesions are associated with mild or no clinical
symptoms.
(iv) Contraindications to craniotomy (e.g., high anesthesia
risk and anticoagulation).
Advantages
(i) Prompt symptom relief e.g., from obstructive
hydrocephalus, mass eﬀect; midline shift, intratumoral, or
intracerebral bleed.
(ii) No size limit.
(i) Outpatient day only procedure.
(ii) Concurrent chemotherapy or imminent treatment
protocol, especially antiangiogenesis therapy.
Disadvantages (i) Depends on expertise of surgeon.
(ii) Lesion needs to be surgically accessible.
(i) Depends on expertise of radiosurgery team.
(ii) Lesion needs to be favourable that is, size <3cm, solid
tumor, with homogenous enhancement and minimal
vasogenic edema, no hydrocephalus.
the RTOG recursive partitioning analysis to 74 patients
with cerebral metastases from melanoma produced median
survival of 10, 6, and 2 months, respectively, for RPA Classes
I–III, respectively, with a median survival of 5.5 months for
the entire group [5].
Initial management includes the use of steroids, typically
4–16mg of dexamethasone per day. This usually results in
rapid symptomatic, but often short-term, improvement in
approximately 50% of patients. Whole brain radiation ther-
apy may produce a small survival advantage compared with
steroidsaloneandmayallowreductioninthesteroiddose.In
addition to whole brain radiation therapy, surgical removal,
or stereotactic radiosurgery of a dominant and symptomatic
lesion should be considered. Conversely, patients with a poor
performance status who have not responded to steroids may
be better treated with supportive care.
The technique of whole brain radiation therapy is a pair
of parallel opposed lateral 6MV photon ﬁelds. Commonly
used regimens are 20Gy in 5 fractions and 30Gy in 10
fractions. For good performance patients with minimal
extracranial disease, there might be an advantages for
higher dose of whole brain radiation therapy based on a
retrospective study [14]. Rades et al. compared the outcomes
of 33 patients treated with 30Gy in 10 fractions with 18
patients treated with higher doses (40Gy in 20 fractions
or 45Gy in 15 fractions). In the multivariate analysis,
higher doses (p=0.010), less than four brain metastases
(p=0.012), no extracranial metastases (p = 0.006), and RPA
class 1 (p = 0.005) were associated with improved overall
survival.
In an attempt to improve survival of patients with
multiple brain metastases,radiation hasbeen combined with
a variety of chemotherapy agents, including temozolomide,
thalidomide, and fotemustine without much success [15–
18]. The most recent study is a phase 2 study combining
whole brain radiation therapy (30Gy in 10 fractions) with
temozolomide and thalidomide in 39 patients [16]. The
response rate was 7.6% and a median time to progression of
7w e e k s .
5. The Role of StereotacticRadiosurgery in
Singleor Oligometastases
The term radiosurgery was originally coined by Lars Lek-
sell to describe the use of a multisource cobalt system
(Gamma Knife) to deliver radiation to a deﬁned target
using stereotactic principle. It aims to deliver an ablative
dose to the target while limiting the dose to surrounding
normal tissue. The latest version of the Gamma Knife
(Perfexion) uses 192 cobalt sources arranged circumferen-
tially in a noncoplanar fashion, permitting smaller doses to
the surrounding normal brain tissue and a lower integral
dose. The associated improvements in planning software
and design modiﬁcations have resulted in the ability to
treat multiple targets in one session [19]. Historically, this
has relied on frame-based stereotactic approaches that can
accurately localise the tumour and target the beam in three-
dimensional space. Options now include frameless image-
guided approaches such as ﬁxed beam intensity-modulated
radiotherapy, helically delivered intensity-modulated radio-
therapy (TomoTherapy), and image-guided robotic radio-
surgery (Cyberknife). Arc-based intensity-modulated radio-
therapy techniques (VMAT and RapidArc) can also achieve
highly conformal image-guided treatment in very short
treatment times [20]. Linear accelerator-based stereotactic
radiosurgery will use a limited number of ﬁelds, usually (but
not always) in a coplanar fashion.
The dose of radiosurgery depends on the size of the
target lesion and the location. The RTOG 90-05 study
was designed to determine the maximum tolerable dose of
radiosurgery in patients with recurrent previously irradiated
brain metastases (excluding lesions in the brain stem) [21].
The maximum tolerable doses of single fraction radio-
surgery for patients with recurrent previously irradiated
brain metastases were 24Gy, 18Gy, and 15Gy for tumors
≤20mm, 21–30mm, and 31–40mm in maximum diameter,
respectively. In the multivariate analysis, those who were
treated on a linear accelerator (versus the Gamma Knife)
had a 2.84 greater risk of local progression. However there4 International Journal of Surgical Oncology
are no randomised data showing clear superiority of any one
stereotactic radiosurgery system.
Mathieu et al. from the University of Pittsburgh reviewed
theexperienceof244patientswith754melanomametastases
treated with Gamma Knife radiosurgery without adjuvant
whole brain radiation therapy [22]. Local control was
achieved in 86.2% of the metastases. Overall, 54 patients
(30.9%) had progression of at least one metastasis after
radiosurgery. The median time to progression was 2.9
months. Fifty-one patients (24.8%) underwent whole brain
radiation therapy after radiosurgery because of the devel-
opment of multiple new brain lesions. Multiple lesions and
failure to provide systemic immunotherapy were predictors
for the occurrence of new brain metastases, which developed
in 41.7% of the patients. Progressive cerebral disease was the
cause of death in 40.5% of the patients. Corticosteroids were
not needed or were discontinued after radiosurgery in 52.4%
of the patients. On multivariate analysis, the use of whole
brain radiation therapy was not a factor that inﬂuenced local
control or distant intracranial control (p = 0.061). A more
recent update of the University of Pittsburgh’s experience
on 333 consecutive patients with 1570 metastatic melanoma
lesions treated with Gamma Knife radiosurgery showed the
long-term local control rate was 73% and the actuarial
survival rates were 70% at 3 months, 47% at 6 months, 25%
at 12 months, and 10% at 24 months [23]. About 25% of
259 patients who had followup imaging after stereotactic
radiosurgery had evidence of delayed intratumoral haem-
orrhage. Factors associated with longer survival included
controlled extracranial disease, better performance status,
fewer number of brain metastases, no prior use of whole
brain radiation therapy or chemotherapy, treatment with
immunotherapy, and no intratumoral hemorrhage before
radiosurgery.
The potential morbidity of stereotactic radiosurgery
includes progression or worsening of cerebral oedema symp-
tomatic in 4–6% of patients within 1-2 weeks of treatment,
seizures within 1-2 days in 2–6%, and delayed radiation
necrosis in 2–11% [21, 24, 25]. This risk increases with prior
treatment, larger volumes treated (both larger lesions and
larger numbers of lesions), and larger doses delivered.
6. The Role of Whole Brain Radiation
Therapy in Melanoma after
Local Treatmentof Metastases
The role for whole brain radiation therapy after surgery
or stereotactic radiosurgery of the single or oligometastasis
is controversial and there is no level 1 evidence in this
scenario. The rationale of whole brain radiation therapy is
to treat microscopic disease at the site of initial metastasis
and elsewhere in the brain to maintain long-term cerebral
control. Adjuvant systemic therapy is generally not used as
the brain is considered a sanctuary site for chemotherapy
although this assumption has been recently challenged by
responses in the patients with B-Raf mutant melanoma
treated with B-Raf inhibitor [26]. However opponents of
whole brain radiation therapy argue that melanoma is
radioresistant and that whole brain radiation therapy can
potentially cause late neurocognitive deﬁcits. The Australia
and New Zealand Melanoma Trials Group (ANZMTG)
and Trans-Tasman Radiation Oncology Group (TROG) are
conducting a phase 3 randomised trial to address the role of
whole brain radiation therapy after local treatment of 1 to 3
melanoma metastases [27]. Eligible patients are randomised
to whole brain radiation therapy or observation after their
local treatment of the brain metastasis. The primary end
point of the trial is distant intracranial control. This trial
also includes detailed neurocognitive and quality of life
assessments.Untilthis trialisreported, clinicians willhaveto
rely on data from other randomised trials included patients
with metastatic disease from all histologies.
Several randomised studies including metastasis from
all histologies have provided good evidence for the use
of whole brain radiation therapy after local treatment of
oligometastases in terms of an improvement in intracranial
control. The number of patients with melanoma in these
trials is typically small. Aoyama et al. compared whole
brain radiation therapy and stereotactic radiosurgery (65
patients) to stereotactic radiosurgery alone in patients with
1–4 brain metastases of any histology [28]. Over 65% of the
patients had metastatic lung cancer, while the number of
melanoma patients per arm was not mentioned. The whole
brain radiation therapy dose was 30Gy in 10 fractions over 2
weeks. There was no diﬀerence between the two groups with
respect to overall survival, neurological toxicity, neurological
functional preservation, and neurological death. The median
survival time was 7.5 months with whole brain radiation
therapyplus stereotacticradiosurgerycomparedto8months
withstereotacticradiosurgeryalone.The12-monthactuarial
brain tumour local recurrence rate was 46.8% in the whole
brain radiation therapy plus stereotactic radiosurgery group
and 76.4% in the stereotactic radiosurgery alone group
(p = 0.001). Fifty-ﬁve patients had new brain metastases at
distant sites (21 in the whole brain radiation therapy plus
stereotactic radiosurgery group and 34 in the stereotactic
radiosurgery-alone group). The 12-month actuarial rate of
developing distant brain metastases was 41.5% in the whole
brain radiation therapy plus stereotactic radiosurgery group
and 63.7% in the stereotactic radiosurgery-alone group (p =
0.003). The univariate analysis showed that patients with 2–4
metastases had a higher risk for developing distant intracra-
nial disease than those with single metastasis (p = 0.03),
but this did not reach signiﬁcance on multivariate analysis
(p = 0.06).
More recently, EORTC reported a randomized trial
of 359 patients with 1 to 3 brain metastases from all
solid tumours randomised to either observation or whole
brain radiation therapy of 30Gy in 10 fractions after local
treatment (surgery or stereotactic radiosurgery) [29]. The
majority (53%) of patients had primary lung cancer and
only 5% had metastatic melanoma. After surgery, at 2
years, whole brain radiation therapy signiﬁcantly reduced
the probability of relapse at initial sites from 59% to 27%
(p=0.001) and at distant intracranial sites from 42% to
23% (p=0.008). After stereotactic radiosurgery, whole brain
radiation therapy reduced the probability of relapse at initialInternational Journal of Surgical Oncology 5
sites from 31% to 19% (p=0.04) and at distant intracranial
sites from 48% to 33% (p=0.023) at 2 years. The median
progression-free survival was slightly longer in the whole
brain radiation therapy arm compared with the observation
arm (4.6 months versus 3.4 months; p=0.02) but there
was no diﬀerence in overall survival between the two arms.
Eighty-one percent of the patients had single metastases but
therewasnoanalysisofoneversusmorethanonemetastases.
This trial included neurocognitive and the quality of life
assessments which have not yet been reported.
There are also a number of single institution retro-
spective series in melanoma patients with their inherent
selection biases. Fife et al. reviewed the outcomes of 686
patients at the Sydney Melanoma Unit (now the Melanoma
Institute Australia) [4]. There was no signiﬁcant diﬀerence
in the median survival between the 158 patients treated
with surgery and whole brain radiation therapy and the 47
patients treated with surgery alone (8.9 months versus 8.7
months, p=0.21). Sampson et al. also reported no diﬀerence
in median survival in patients treated with whole brain
radiation therapy after surgery or surgery-alone patients
(median survival of 9 months, p = 0.99). However, patients
treated with whole brain radiation therapy were more likely
to remain without neurological deﬁcits or experience an
improvement (81.7%) after completion of therapy than
those who did not (57.7%, p = 0.01).
Selek et al. reported on 103 patients with 153 intracranial
melanoma metastases treated with stereotactic radiosurgery
[30]. Sixty-one patients (59%) had single brain metastasis.
Treatment was stereotactic radiosurgery alone (61 patients),
stereotactic radiosurgery with whole brain radiation therapy
(12 patients), and salvage stereotactic radiosurgery after
whole brain radiation therapy (30 patients). The overall
incidence of distant brain metastasis-free survival did not
diﬀer signiﬁcantly between the group that received initial
stereotactic radiosurgery alone and the group that received
stereotactic radiosurgery and whole brain radiation therapy
(17.6%versus0%, p=0.27).Howeverthisstudydidnothave
the statistical power to detect a diﬀerence in distant brain
metastasis free survival. The initial number of brain lesions
(single versus multiple) was the only factor with a signiﬁcant
eﬀect on distant brain metastasis-free survival at 1 year:
23.5% for single metastases and 0% for multiple lesions (p<
0.05). Samlowski et al. performed a retrospective analysis
of 44 melanoma patients with ﬁve or less brain metastases
treated with stereotactic radiosurgery and showed that the
addition of whole brain radiation therapy did not improve
survival [13]. Buchsbaum et al. reviewed 74 patients with
melanoma brain metastases [5]. Survival analysis showed
that combined treatment of local and whole brain radiation
therapy oﬀered signiﬁcantly better survival (p<0.0001).
The median survival was 8.8 months for the combined
therapygroup,4.8monthsforthelocal-therapy-alonegroup.
However, whole brain radiation therapy did not improve the
intracranial distant control.
MD Anderson reported a series of patients with solitary
melanoma brain metastasis and no extracranial disease [31].
Twenty-two patients received surgical excision and whole
brain radiation therapy whole brain radiation therapy and
12 patients were treated with surgery alone. Despite the
small sample size, intracranial recurrence rates favoured
the combination (5/22 versus 9/12 surgery alone, p=0.01).
Median overall survival was 18 months in the combination
therapy group versus 6 months for surgery alone (p=0.002).
These data argue that whole brain radiation therapy can
decrease intracranial progression and may even convey a
survivalbeneﬁtinpatientswithoutactiveextracranialdisease
as a competing cause of death.
One concern of delivering whole brain radiation therapy
after local treatment of oligometastases is the potential
neurological deﬁcit. Preclinical and early clinical evidence
suggests that a neural stem cell compartment in the
hippocampus is central to the pathogenesis of neurocog-
nitive deﬁcits observed after cranial irradiation. Modern
intensity-modulated radiotherapy technologies, such as heli-
cal tomotherapy and volumetric modulated arc therapy can
conformally avoid the hippocampus during whole brain
radiation therapy and therefore potentially reduce the risk
of neurocognitive deﬁcit. A RTOG review of 371 patients
withlessthan10brainmetastasisfromallhistologiesshowed
that only 3% of the metastatic deposit were within the
5mm region around the hippocampus and none within
the hippocampus itself [32]. There is an ongoing clinical
trial (RTOG 0933) examining the eﬀect of hippocampal
avoidance whole brain radiation therapy technique on the
neurocognitive function in patients with brain metastases
from all histologies.
7. Conclusions
Brain metastasis is a common development in patients with
metastatic melanoma. The role of radiation therapy in the
management is highly variable due to the natural history of
the disease. To provide optimal management of the patient
with melanoma, the radiation oncologist is an integral part
of the multidisciplinary team. Although there have been no
randomizedtrialsespeciallyinpatientswithmelanomabrain
metastasis, treatment can be guided by the application of
evidence for the treatment of brain metastasis in general.
A promising new approach to deliver radiation therapy
while sparing the hippocampus will hopefully improve the
therapeutic ratio and minimise potential long term toxicity.
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